Previous 10 | Next 10 |
Penny stocks typically trade for less than $5 per share and tend to be highly volatile. But this wild price action has attracted so many retail traders over time. Whether we’re talking about OTC penny stocks or ones trading on the NYSE or NASDAQ, there are hundreds to choose from...
NLS Pharmaceutics ( NASDAQ: NLSP ) said the Japanese Patent Office is granting a patent for the proprietary formulation of Quilience (Mazindol ER). The company said the patent — application 2018-546837 —will cover oral formulations containing immedia...
Key patents now granted in major markets including the U.S., Europe, Japan, Canada & South Korea Patent claims cover use of the Company's lead product candidate, Quilience® (mazindol ER) in attention deficit hyperactivity disorder (ADHD), narcolepsy & idiopathic hypersomni...
Buying Penny Stocks on July 22nd? Here’s What You Need to Know After another positive day of trading penny stocks and blue chips, investors are enthused about the future. To understand how to make money with penny stocks , investors need to have a full understanding of what i...
ZURICH, SWITZERLAND / ACCESSWIRE / July 21, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company") , a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex centr...
NLS Pharmaceutics (NASDAQ:NLSP) on Friday said it got a notice from Nasdaq that it was not in compliance with a listing rule on minimum bid price requirement. The Swiss clinical-stage biopharmaceutical company has 180 days to regain compliance. The notice has no immediate effect on the tradin...
ZURICH, SWITZERLAND / ACCESSWIRE / June 10, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) , (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central ...
NLS Pharmaceutics (NASDAQ:NLSP -1.8%) has announced that Chad C. Hellmann has been appointed to the position of Chief Financial Officer. Serving most recently as CFO and co-portfolio manager of Arcus Ventures, Mr. Hellmann brings to NLS significant expertise in developing and implementing ope...
ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) , (NASDAQ:NLSPW) ("NLS" or the "Company") , a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central n...
60-patient enrollment target met plus 12% over-enrollment; top-line Phase 2a results expected to be presented during the European Sleep Research Society Congress in September 2022 Nearly 90% of patients completing the Phase 2a trial to date have rolled over into the open label extensio...
News, Short Squeeze, Breakout and More Instantly...
NLS Pharmaceutics Ltd. Company Name:
NLSP Stock Symbol:
NASDAQ Market:
NLS Pharmaceutics Ltd. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.3% to $111.59 on volume of 240,827,673 shares Lipella Pharmaceuticals Inc. (LIPO) rose 122.5% to $0.8992 on volume of 193,926,302 shares PROSHARES TRUST (SQQQ) fell 0.5% to $9.05 on volume of 150,372,371...
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy platform Each of Kadimastem and NLS Pharmaceutics has received commitments of support f...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...